CRISM Therapeutics (LON:CRTX – Get Free Report) released its quarterly earnings data on Monday. The company reported GBX (2.60) earnings per share for the quarter, Digital Look Earnings reports.
CRISM Therapeutics Price Performance
LON:CRTX opened at GBX 9.85 on Wednesday. The firm has a market capitalization of £7.80 million, a P/E ratio of -1.93 and a beta of 0.58. The business has a 50 day simple moving average of GBX 10.41 and a 200 day simple moving average of GBX 11.12. CRISM Therapeutics has a 12-month low of GBX 8 and a 12-month high of GBX 18.50.
About CRISM Therapeutics
ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.
Further Reading
- Five stocks we like better than CRISM Therapeutics
- AutoZone Shifts Gears, On Track to Reverse Course and Price Recovery
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
Receive News & Ratings for CRISM Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISM Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
